Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prediction of Cardiotoxicity Using Serum N-Terminal Pro-B-Type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab.

Next Previous
Trial Profile

Prediction of Cardiotoxicity Using Serum N-Terminal Pro-B-Type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Anthracyclines
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Biomarker
  • Acronyms CATS

Most Recent Events

  • 15 Apr 2013 Planned end date changed from 1 Feb 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 15 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 26 Jul 2011 Planned End Date changed from 1 Feb 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top